Skip to main content
Clinical Trials/EUCTR2020-001457-43-FR
EUCTR2020-001457-43-FRActive, not recruitingPhase 1

Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS

APHP0 sites550 target enrollmentStarted: April 2, 2020Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
APHP
Enrollment
550

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1.Age = 18 years
  • 2.Admitted to ICU within 48 hours
  • 3.Confirmed or highly suspected COVID-19 infection
  • 4.Acute hypoxemic respiratory failure (PaO2 <70 mmHg or SpO2<90% on room air or tachypnea>30/min or labored breathing or respiratory distress; need for oxygen flow >=6L/min)
  • 5.Any treatment intended to treat the SARS-CoV-2 infection (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 400
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 150

Exclusion Criteria

  • 1. Patient moribond
  • 2. Grossesse ou allaitement
  • 3. Corticothérapie à long terme à une dose de 0,5 mg / kg / j ou plus
  • 4. Infection bactérienne, fongique ou parasitaire active et non traitée
  • 5. Absence de consentement éclairé écrit du patient ou d'un représentant légal, le cas échéant
  • 6. Hypersensibilité à la Dexamethasone ou l’un de ces excipients
  • Pour les patients non ventilés mécaniquement, les critères de non-inclusion supplémentaires sont:
  • 7. Facteurs anatomiques empêchant l'utilisation d'une canule nasale
  • 8. Hypercapnie indiquant une VNI (paCO2 = 50 mmHg)

Investigators

Sponsor
APHP

Similar Trials